Upgrade to SI Premium - Free Trial

Eli Lilly & Co. (LLY) to Present Key Primary & Secondary Endpoint Data for Lasmiditan in Phase 3 SPARTAN study

September 11, 2017 5:50 AM
Eli Lilly and Company (NYSE: LLY) will present key primary and secondary endpoint data for lasmiditan, an investigational, oral ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Hot Corp. News Management Comments

Next Articles